Abiopharma

IVERIC bio Inc (the company became a subdivision of the company Astellas Pharma Inc. (TSE: 4503)) (ISEE) Announces Clinical Trial Update IVERIC bio Inc (the company became a subdivision of the company Astellas Pharma Inc. (TSE: 4503)) (ISEE) provided an update on its clinical development programs. Clinical Development Highlights:

• Drug Program: results, trial
• Diseases/Conditions: Zimura® (avacincaptad pegol)
• Clinical Stage: Phase 3, clinical trial
• Collaboration: Operational Highlights and
  • expected injections (drug and sham) based on the total number of patients enrolled in the trial. The Company considers injection fidelity to be the most important and stringent measure of patient retention because it reflects the timely administration of the drug or sham into the patient’s eye. In June 2022
  • Expected in September of this Year--GATHER2 Patient Retention Continues to Exceed Expectations with a 12-Month Injection Fidelity Rate of 92.5% –-Agreement for up to $250 Million in Non-dilutive Debt Financing Secured --Exclusive License Entered into for Sustained Release Delivery Technology for Zimura® -- Conference Call and Webcast Today, July 26, 2022